According to research reviewed by Gram, enlicitide received its first approval in the United States on July 16, 2026. It is approved as an add-on to diet and exercise to lower LDL cholesterol in adults with high cholesterol, including inherited familial hypercholesterolaemia. Specific effect sizes should be checked in trial reports.
According to research reviewed by Gram, enlicitide, an investigational cholesterol-lowering drug from Merck Sharp & Dohme, received its first approval in the United States on July 16, 2026. It is designed to lower LDL cholesterol, often called “bad” cholesterol, in adults with high cholesterol, including people with an inherited form called heterozygous familial hypercholesterolaemia. Enlicitide belongs to a drug group called PCSK9 inhibitors, which help the liver remove more LDL from the blood. It is meant to be used alongside diet and exercise, not in place of them. This review traces the development milestones that led to approval. Because it summarizes the drug’s path to market rather than reporting new patient data, readers should consult the full prescribing information and clinical trial reports for specific effect sizes and safety details.
Key Statistics
A 2026 review published in the journal Drugs reported that enlicitide received its first U.S. approval on July 16, 2026, as an add-on to diet and exercise for adults with high cholesterol.
The approval covers adults with hypercholesterolaemia, including people with heterozygous familial hypercholesterolaemia, an inherited form of high LDL cholesterol that is present from birth.
The Quick Take
- What they studied: This review asks how enlicitide was developed and what led to its first approval as a treatment for high cholesterol.
- Who participated: The review does not enroll patients. It summarizes the drug’s development history and regulatory approval, so no participant group is studied directly. The approval covers adults with high cholesterol, including people with an inherited form of the condition.
- Key finding: Enlicitide received its first approval in the United States on July 16, 2026. It is approved as an add-on to diet and exercise to lower LDL cholesterol. The abstract does not report specific percentage reductions, so readers should check the trial data for those numbers.
- What it means for you: If you have high cholesterol, this approval may add a new option to your treatment list. It is not a replacement for a healthy diet, regular exercise, or other prescribed medicines. Talk with your doctor before making any changes, since they can judge whether it fits your health history.
The Research Details
This is a review article published in the journal Drugs, part of a series that tracks new medicines from development through their first approval. Rather than running a new experiment, the authors gather the key milestones in enlicitide’s development into one summary. This type of article is useful for understanding the overall path a drug took from early research to regulatory decision.
The review focuses on enlicitide’s approval for hypercholesterolaemia, meaning high levels of cholesterol in the blood. The approval covers adults who need to lower their LDL cholesterol, including those with heterozygous familial hypercholesterolaemia, an inherited condition that raises cholesterol from birth. The review places this approval in the context of the drug’s development by Merck Sharp & Dohme.
Because the article summarizes information from the development process and regulatory decision, it highlights what regulators concluded, not every detail of the studies behind that decision. Readers who want the full evidence should look at the original clinical trial publications and the official prescribing information.
A review like this helps clinicians, patients, and researchers see how a new drug moved from development to approval in one place. It explains the regulatory milestones and the intended use of the medicine. This makes it easier to understand where enlicitide fits among existing cholesterol treatments.
The publication is in Drugs, a peer-reviewed pharmacology journal, which means the article was reviewed by outside experts before publication. Review articles depend on the quality of the studies they summarize, so the overall reliability is tied to the underlying trials. The abstract does not report trial sizes or detailed results, so readers should verify those numbers in primary sources.
What the Results Show
The main outcome described in this review is the first approval of enlicitide in the United States on July 16, 2026. The drug is approved as an adjunct, meaning an add-on, to diet and exercise. Its purpose is to reduce LDL cholesterol in adults with hypercholesterolaemia.
LDL cholesterol is a major contributor to plaque buildup in artery walls. Lowering LDL is a central goal in preventing heart attacks and strokes. Drugs that act on the PCSK9 pathway work by helping the liver clear more LDL from the bloodstream, which is why they are often used when diet and standard medicines are not enough.
The approval specifically includes people with heterozygous familial hypercholesterolaemia, a genetic condition that causes very high LDL levels from a young age. This inclusion matters because these patients often have the greatest need for stronger cholesterol-lowering options.
The review does not provide the size of the percentage drop in LDL seen in trials. Readers should look to the original trial results to understand how much LDL was reduced and how consistently patients responded.
The review notes that enlicitide’s approval is meant to be an add-on to lifestyle changes, which means lifestyle habits remain part of treatment. The approval also signals that regulators judged the drug’s benefits to outweigh its known risks for the approved population. Specific safety findings, side effects, and long-term outcomes are not detailed in the abstract, so they should be checked in the full article or prescribing information.
Enlicitide belongs to the PCSK9 inhibitor class, which already includes approved treatments that are typically given by injection. Enlicitide is being developed as a different option within this class, and its approval adds to the choices available for lowering LDL cholesterol. Comparisons of effectiveness, convenience, and cost should be drawn from head-to-head or trial data rather than from this overview alone.
This review summarizes development milestones and regulatory approval, so it does not present new data from patients. The abstract does not report trial sizes, percentage reductions in LDL cholesterol, or safety details, which limits how much readers can judge the drug’s effectiveness from this source alone. Long-term results beyond the trial periods may still be emerging. Readers should treat this article as a starting point and review the primary trial reports and official labeling before drawing firm conclusions.
The Bottom Line
Based on the regulatory approval described in this review, enlicitide may be a useful option for adults with high LDL cholesterol who need additional lowering on top of diet, exercise, and existing treatment. Confidence in this recommendation is moderate, because the approval reflects regulatory review, while the detailed trial data are not summarized here. Decisions should be made with a doctor who can review individual risk and the full evidence.
Adults with high cholesterol, especially those who have not reached their LDL goals with current treatments, and people with heterozygous familial hypercholesterolaemia may want to ask their doctor whether this medicine is appropriate. Clinicians who manage cholesterol may find the approval relevant to their treatment planning. People without high cholesterol, or those whose LDL levels are already well controlled, are unlikely to need it based on this information.
Cholesterol-lowering medicines usually take a few weeks to show a measurable effect on blood tests, and doctors often recheck LDL levels after about 4 to 12 weeks. Benefits for heart health build over months to years, because the goal is to reduce long-term plaque buildup. Realistic expectations should be discussed with a healthcare provider who can set a monitoring schedule.
Frequently Asked Questions
What is enlicitide and what is it used for?
Enlicitide is a cholesterol-lowering drug from Merck Sharp & Dohme in the PCSK9 inhibitor class. It received U.S. approval on July 16, 2026, to lower LDL cholesterol in adults with high cholesterol when used alongside diet and exercise.
How do PCSK9 inhibitors lower cholesterol?
PCSK9 inhibitors block a protein that normally reduces the number of LDL receptors on liver cells. With more receptors available, the liver removes more LDL cholesterol from the blood, which lowers overall LDL levels.
Who can use enlicitide according to its approval?
Enlicitide is approved for adults with hypercholesterolaemia, including those with heterozygous familial hypercholesterolaemia. It is intended as an add-on to diet and exercise, so patients should discuss whether it fits their health needs with a doctor.
Is enlicitide a replacement for diet and exercise for high cholesterol?
Enlicitide is not a replacement for diet and exercise. Its approval describes it as an adjunct, meaning an add-on, to lifestyle changes. Healthy eating, regular physical activity, and other prescribed treatments remain part of a complete cholesterol plan.
Want to Apply This Research?
- Log your LDL cholesterol result from each lab test along with the date and any medication changes. Record the dose and start date of any cholesterol medicine, so you can see how LDL responds over time. Track the result against your doctor’s target number.
- Use the app to schedule and log lab tests and medication refills, so that you do not miss a dose or follow-up. Set a weekly reminder to log a few heart-healthy habits, such as servings of vegetables, minutes of walking, or meals cooked at home. Pair these habits with any prescribed treatment rather than replacing them.
- Plan to review your LDL trend every few months, with lab tests scheduled according to your doctor’s guidance. Keep a long-term record of blood test results, medication changes, and any side effects you notice. Share this log at each appointment so your care team can adjust your plan based on your full history.
This article summarizes a review about the development and approval of a prescription cholesterol medicine. It is for general information only and is not medical advice. Do not start, stop, or change any medication without talking to a qualified healthcare provider, who can evaluate your individual health history, risks, and treatment options.
This research translation is published by Gram Research, the science division of Gram, an AI-powered nutrition tracking app.